Synergus RWE joins the IGES group to become leader in European market access for medical devices and digital health
14 Jul 2023

Combining the strategic services with the best in local execution

The IGES group has acquired a majority stake in Synergus RWE to create the leading market access consultancy offer for medical devices and digital health, in combination with the existing companies in the group.

Synergus RWE supports clients to develop pan-European strategies for market access and the need for evidence. The existing companies in the IGES group provides a unique track record of successful implementation:

  • AiM, Germany
  • Meditech Access, France
  • Device Access UK, United Kingdom

Together we can help companies from strategy to successful local execution.

Synergus RWE also provides market access hands-on support in the Nordic Countries and the use of Scandinavian registries to develop Real-World-Evidence.


Founded in 2007, AiM has supported the medical device industry in market access in the DACH countries for more than 15 years. To this day, AiM has concluded more than 900 projects for more than 250 clients, including numerous successful reimbursement applications (NUB, OPS, DRG, evidence dossiers).

Meditech Access

Since 2012, Meditech Access supports MedTech companies and Startups in France and Belgium, securing reimbursement and early funding for their medical devices and digital health solutions.

With 50+ annual reimbursement successes, they are pivotal in introducing innovative medical devices and leading the early access pathway (PECT) with the highest number of successful dossiers to date.

Device Access

Device Access was established in 2010 to support medical device and diagnostic and digital companies access the UK Healthcare system the National Health Service or NHS.

To date, Device Access has helped over 50 companies navigate various NICE evaluation programmes for approval.

“By combining the medtech companies of the IGES group with Synergus RWE, we become one of the leading consulting companies in this segment.”, said Professor Dr Bertram Häussler, Chairman of the IGES Management Board. "The acquisition will likewise enable us to provide utility of the rich Scandinavian registries for Real-World-Evidence studies."

Synergus RWE founder, Mattias Kyhlstedt, will continue to steer Synergus RWE as CEO from the company's headquarters in Stockholm. “I am excited about the opportunity how this will allow us to jointly support our clients from strategy to local execution. This will give us a unique position to support companies to optimize time to market for innovative products.”